Jean-François Chatal, a pioneer in nuclear medicine, is an emeritus professor at the University of Nantes and the author of 204 publications. He served as head of the nuclear medicine departments at the Nantes University Hospital (CHU) and the cancer institute (ICC). He founded an INSERM laboratory at the University of Nantes (CRCINA) dedicated to the diagnostic and therapeutic use of radiolabeled monoclonal antibodies in oncology. In collaboration with Jacques Barbet from Immunotech, they were the first to demonstrate the relevance of pretargeting based on antibody use with a survival benefit of a radioimmunotherapeutic solution in a solid tumor. Their results targeting thyroid cancer were published in 2006 in the Journal of Clinical Oncology. Together with colleagues at the University of Nantes and with support from the Pays de la Loire region and the French government, Jean-François initiated the installation of a high-energy/high-intensity cyclotron, Arronax, in 2010 for the production of innovative radionuclides. He is also a co-founder of Atlab-Pharma in 2008 (sold to Telix in 2018), a company dedicated to the industrial development of radiolabeled antibodies for radioimmunotherapy, and of Naogen Pharma founded in 2016, a company developing a Rubidium-82 generator for cardiac imaging by Positron Emission Tomography (PET). In 2013, he was honored in Paris with the “Antoine Beclere Medal” awarded for his work in the development of nuclear medicine.

Sylvain Fanier has dedicated his career to overseeing and leading the development of several global medical innovations in the healthcare sector, including neurosurgery, oncology, pain management, cardiovascular, electrophysiology, atrial fibrillation, 3D navigation systems, ultrasound, signal processing, radiation protection, shock waves, and molecular imaging and alpha-immunotherapy. He brings to the company leadership in strategy and a global perspective on business and financing, acquired over the past 30 years in large groups such as Johnson & Johnson and CR Bard, as well as in medical start-ups. Specializing in disruptive medical innovation, he has supported the success of innovative companies such as Lemerpax, Cardioinsight, Sonoscanner, Soundbite Medical Solutions, Surgivisio, and Med-Innov through his consulting firm, Novariver. He holds a degree in Biochemistry and a Master’s in Physiology from Paul Sabatier University in Toulouse. He also holds an EMBA from ESSEC, Paris, France. Sylvain is a board member of Soundbite Medical Solutions Inc. (Montreal, Canada) and a member of the strategic committees of Ecential Robotics SAS (Grenoble, France), Naogen Pharma, and Atonco (Nantes, France).

Alexandra holds a Doctor of Pharmacy degree with more than twenty years of experience in Pharmaceutical Development, Quality Assurance, and CMC Regulatory Affairs. She began her career researching protein vectorization at the MINT – INSERM1066 laboratory at the University of Angers. Alexandra then worked on bringing medicines to market within pharmaceutical laboratories, start-ups, and consulting firms. She managed several pharmaceutical development projects and drafted around ten marketing authorization applications (quality section) at LFB, Biogaran, and ProductLife Group. Alexandra Paillard also contributed to setting up the quality system at the start-up DelleD up to obtaining authorization to open the Exploiting Pharmaceutical Establishment, and was responsible for Quality Assurance at Zach System, a manufacturer of pharmaceutical active ingredients. Today, Alexandra applies her experience at Atonco to the development of innovative radiopharmaceutical products in compliance with radiopharmaceutical regulations. Alexandra holds a Doctor of Pharmacy degree from the University of Angers and a PhD in pharmaceutical technology from the University of Paris-Sud.

Jacques Barbet brings to Atonco over 40 years of research experience in various fields, particularly in targeting radionuclides to tumor cells for imaging and therapy. Trained as an engineer at the École Polytechnique in Paris, he obtained his doctorate at the University of Paris VI and was appointed Research Director by the CNRS. He settled in Marseille at the Centre d’Immunologie de Marseille-Luminy, then joined Immunotech SA as head of the pretargeting project. He subsequently joined Jean-François Chatal’s group in Nantes to help set up GIP Arronax for more than 4 years. He contributed greatly to the development of nuclear medicine research in Nantes by leading the European FP7 TARCC project, the regional research program NucSan, and the PIA ArronaxPlus excellence equipment. In the meantime, he was one of the founding shareholders of Chelatec, Atlab Pharma (now acquired by Telix), and OGD2 Pharma. Retired in 2015 as a research director (exceptional class), he acts as principal scientific advisor for GIP Arronax, Chelatec, OGD2 Pharma, and Atonco.

Adrien has more than 15 years of experience in the radiopharmaceutical industry, first as a pharmacist at Advanced Accelerator Applications (AAA, Novartis), then as chief pharmacist, president, and general manager of PETNET Solutions France (Siemens). Subsequently, Adrien served as project director at Atlanpole Biotherapies, the Nantes competitiveness cluster. The mission of the Pôle Santé Nord-Ouest, on behalf of the regional institution, is to assist public decision-makers in defining strategies to support the development of the Nantes radiopharmaceutical sector. Adrien advises various radiopharmacy leaders (Ipsen, Arronax). He has been involved in the development of innovative projects for several radiopharmaceutical companies since 2018 and has developed extensive experience in industrial operations, quality, and regulatory affairs with a broad network in the field of nuclear medicine. Adrien holds a Doctor of Pharmacy degree from the University Claude Bernard of Lyon, France, and a bachelor’s degree in chemical process engineering from Polytechnique Montréal, Canada.

Denis brings diverse experience in patient care: clinical research on medical devices, pharmaceutical drug development, central laboratories, genomics, medical imaging, and cell therapy, within organizations such as Sandoz, Aventis, Genome Quebec, and the Montreal Heart Institute, at both national and international levels. He led one of Canada’s largest population genomics registries and has successfully conducted clinical research programs leading to US, Canadian, and European approvals. He is a member of the Ordre des administrateurs agréés du Québec. As Clinical Research Director, Denis will work closely with academic clinical research teams to implement Atonco’s clinical studies, including notably the one targeting bladder cancer. Denis holds an MBA from Concordia University, Montreal, and a BSc from Université Laval, Quebec.

Clément Mayeur has more than 15 years of experience in corporate finance. He began his career in the audiovisual sector during the creation of the Orange Sport channel, then at TF1 in the mergers and acquisitions of production companies. In parallel, his career was enriched by entrepreneurial experiences that exposed him to the dynamics of company creation and development. After several years as a financial manager and then CFO in an international environment, he became a shared financial director and specialized in the MedTech and Biotech sectors. He brings to the company his expertise in corporate finance and in the implementation of a rigorous financial organization. He holds a master’s degree from Paris Dauphine University and the University of Reading in business finance, a postgraduate degree in intellectual property from Paris Sorbonne University, and a specialization in corporate finance from EDHEC Business School.